This content is machine translated Psoriasis and metabolic comorbidities: new study data GLP-1RAs showed a valuable dual benefit GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients...…
View Post 7 min This content is machine translated Evidence-based therapy for psoriasis in difficult locations IL-23 inhibition in scalp psoriasis: what’s new? Involvement of the scalp is common in psoriasis patients and can induce considerable distress with sometimes significant effects on quality of life. In addition to new study findings on the...…
View Post 9 min This content is machine translated Psoriasis: intervening in the inflammatory cascade Advantages of early biologic therapy and oral peptide as a beacon of hope The question of whether early biologics treatment can have a lasting effect on the course of psoriasis is the focus of numerous research projects. The GUIDE study investigated the corresponding...…
View Post 9 min This content is machine translated SID Annual Meeting: Highlights Update on inflammatory dermatoses – a concentrated load of innovative power Research teams from different corners of the world presented studies that are characterized by a high level of innovation. In addition to the evaluation of already established therapy options, numerous...…
View Post 8 min This content is machine translated Psoriasis and PsA Biologics, oral peptide and trivalent nanobody – current results and trends Top-line results are available for both Icotrokinra and Sonelokimab, which attest to the great therapeutic potential of these innovative drug candidates. However, there is also extremely interesting new evidence from...…
View Post 5 min This content is machine translated Psoriasis Indications of an increased risk of “leaky gut” Psoriasis sufferers often have invisible inflammation in the small intestine along with a tendency to increased permeability of the intestinal barrier (“leaky gut”), according to recently published research from Uppsala...…
View Post 8 min This content is machine translated Psoriasis treatment with biologics What are the latest trends? Novel oral therapies are currently being researched – promising data from clinical trials is now available. In the field of approved, subcutaneously administered IL-23 and IL-17 antagonists, current real-world data...…
View Post 9 min This content is machine translated Psoriasis in locations that are difficult to treat New study data on IL-23 inhibition When psoriasis manifests in palmoplantar and intertriginous regions or on the nails, this often poses a therapeutic challenge. Several recently presented analyses on the effects of anti-IL-23p19 antibodies currently approved...…
View Post 4 min This content is machine translated Inflammatory memory in psoriasis Timing of biologics therapy is crucial The pathogenesis of psoriasis is complex, but is becoming increasingly better understood. With the modern substance classes of interleukin (IL)-17 and IL-23 inhibitors, highly effective biologics are now available for…
View Post 5 min This content is machine translated SDNTT register data Psychological comorbidities in psoriasis Inflammatory systemic diseases such as psoriasis are associated with a high risk of comorbidity. In addition to cardiometabolic diseases, mental disorders are particularly common in this patient population. As part…
View Post 9 min This content is machine translated System therapy for psoriasis Expanded possibilities thanks to practical innovations Compared to the past, there are now more and more effective systemic therapies available. This has been helped by a surge in innovation that has produced a wide range of…
